KBP is developing an innovative pipeline of New Chemical Entities with known mechanisms of action in areas of unmet medical need in Organ Protection and Infectious Diseases.


KBP-5074 for CV disease/Hypertension in CKD patients – Initiated global Phase 2b in Q1 2018

KBP-7072 for multiple drug resistant infections – Finish Phase 1 – Ready for global Phase 2

KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD – IND Approved & Ready for Phase 1

Read More

Management Team

Johan M.(Thijs) Spoor, MBA, CEO
Nick Hart, CFO
Fred Yang, PhD, CDO
Michael Miernicki, PhD, VP
Vince Benn, PhD/MBA, VP
Jay (Xu-Jie) Zhang, PhD, VP
Jerry Zhong, PhD, MBA, PMP, VP
James McCabe, MD, VP
Pengfei (Murphy) Guo, PhD, AVP
A. Sophia Hurtado, RN, Senior Director

George Bakris, MD (US)
John McMurray, MD (UK)
Bertram Pitt, MD (US)
Faiez Zannad, MD (FR)
Frédéric Jaisser, MD, PhD
Clare Kahn, PhD

Ricard Wunderink, MD (US)

Read More

KBP News

KBP BioSciences to present at Biotech Showcase 2020

KBP BioSciences signs memorandum of understanding with Bullforg AI

KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.

Positive FDA Type B Meeting on KBP-5074

KBP-7072 obtained QIDP and Fast Track Designations

Read More

Contact Us

Jennifer Miao          jennifer.miao@kbpbiosciences.com

116 Village Blvd., Suite 210 Princeton, NJ 08540

Phone: (609) 531-0889 (Office) / (732) 429-0898 (Cell)